Joseph S. Ross

List of Publications by Year
in descending order

		53751	30894
152	11,234	45	102
papers	citations	h-index	g-index

165	165	165	13574
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Exposure to Low-Dose Ionizing Radiation from Medical Imaging Procedures. New England Journal of Medicine, 2009, 361, 849-857.	13.9	1,175
2	Diagnoses and Timing of 30-Day Readmissions After Hospitalization for Heart Failure, Acute Myocardial Infarction, or Pneumonia. JAMA - Journal of the American Medical Association, 2013, 309, 355.	3.8	831
3	Trends in Length of Stay and Short-term Outcomes Among Medicare Patients Hospitalized for Heart Failure, 1993-2006. JAMA - Journal of the American Medical Association, 2010, 303, 2141.	3.8	596
4	An Administrative Claims Measure Suitable for Profiling Hospital Performance on the Basis of 30-Day All-Cause Readmission Rates Among Patients With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2008, 1, 29-37.	0.9	453
5	Guest Authorship and Ghostwriting in Publications Related to Rofecoxib. JAMA - Journal of the American Medical Association, 2008, 299, 1800.	3.8	398
6	Recent National Trends in Readmission Rates After Heart Failure Hospitalization. Circulation: Heart Failure, 2010, 3, 97-103.	1.6	373
7	Trial Publication after Registration in ClinicalTrials.Gov: A Cross-Sectional Analysis. PLoS Medicine, 2009, 6, e1000144.	3.9	339
8	Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012. JAMA - Journal of the American Medical Association, 2014, 311, 368.	3.8	327
9	National Trends in US Hospital Admissions for Hyperglycemia and Hypoglycemia Among Medicare Beneficiaries, 1999 to 2011. JAMA Internal Medicine, 2014, 174, 1116.	2.6	324
10	Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. BMJ: British Medical Journal, 2012, 344, d7292-d7292.	2.4	318
11	Relationship Between Hospital Readmission and Mortality Rates for Patients Hospitalized With Acute Myocardial Infarction, Heart Failure, or Pneumonia. JAMA - Journal of the American Medical Association, 2013, 309, 587.	3.8	307
12	Hospital Volume and 30-Day Mortality for Three Common Medical Conditions. New England Journal of Medicine, 2010, 362, 1110-1118.	13.9	287
13	Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. JAMA - Journal of the American Medical Association, 2020, 323, 734.	3.8	260
14	Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006â€“2013. Diabetes Care, 2017, 40, 468-475.	4.3	249
15	Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010. JAMA - Journal of the American Medical Association, 2017, 317, 1854.	3.8	235
16	Association Between Hospital Penalty Status Under the Hospital Readmission Reduction Program and Readmission Rates for Target and Nontarget Conditions. JAMA - Journal of the American Medical Association, 2016, 316, 2647.	3.8	230
17	Reduction in Acute Myocardial Infarction Mortality in the United States. JAMA - Journal of the American Medical Association, 2009, 302, 767.	3.8	229
18	Association of Changing Hospital Readmission Rates With Mortality Rates After Hospital Discharge. JAMA - Journal of the American Medical Association, 2017, 318, 270.	3.8	176

#	Article	IF	Citations
19	Effect of Blinded Peer Review on Abstract Acceptance. JAMA - Journal of the American Medical Association, 2006, 295, 1675.	3.8	174
20	Cumulative Exposure to Ionizing Radiation From Diagnostic and Therapeutic Cardiac Imaging Procedures. Journal of the American College of Cardiology, 2010, 56, 702-711.	1.2	166
21	National Patterns of Risk-Standardized Mortality and Readmission for Acute Myocardial Infarction and Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2010, 3, 459-467.	0.9	158
22	Regulatory Review of Novel Therapeutics â€" Comparison of Three Regulatory Agencies. New England Journal of Medicine, 2012, 366, 2284-2293.	13.9	146
23	Health Care Insurance, Financial Concerns in Accessing Care, and Delays to Hospital Presentation in Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2010, 303, 1392.	3.8	121
24	Ushering in a New Era of Open Science Through Data Sharing. JAMA - Journal of the American Medical Association, 2013, 309, 1355.	3.8	106
25	Hospital-Readmission Risk â€" Isolating Hospital Effects from Patient Effects. New England Journal of Medicine, 2017, 377, 1055-1064.	13.9	93
26	Time to Publication Among Completed Clinical Trials. JAMA Internal Medicine, 2013, 173, 825.	2.6	92
27	Association of Admission to Veterans Affairs Hospitals vs Nonâ€"Veterans Affairs Hospitals With Mortality and Readmission Rates Among Older Men Hospitalized With Acute Myocardial Infarction, Heart Failure, or Pneumonia. JAMA - Journal of the American Medical Association, 2016, 315, 582.	3.8	90
28	Reporting of Results in ClinicalTrials.gov and High-Impact Journals. JAMA - Journal of the American Medical Association, 2014, 311, 1063.	3.8	87
29	Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011. JAMA - Journal of the American Medical Association, 2015, 314, 604.	3.8	87
30	Use of Ezetimibe in the United States and Canada. New England Journal of Medicine, 2008, 358, 1819-1828.	13.9	85
31	The Importance of Clinical Trial Data Sharing. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 238-240.	0.9	83
32	Variation in US Hospital Emergency Department Admission Rates by Clinical Condition. Medical Care, 2015, 53, 237-244.	1.1	78
33	Use of Fibrates in the United States and Canada. JAMA - Journal of the American Medical Association, 2011, 305, 1217.	3.8	74
34	Participation of the elderly, women, and minorities in pivotal trials supporting 2011â€"2013 U.S. Food and Drug Administration approvals. Trials, 2016, 17, 199.	0.7	66
35	Pharmaceutical Company Payments to Physicians. JAMA - Journal of the American Medical Association, 2007, 297, 1216.	3.8	65
36	Regional Variation in Cardiac Catheterization Appropriateness and Baseline Risk After Acute Myocardial Infarction. Journal of the American College of Cardiology, 2008, 51, 716-723.	1.2	65

#	Article	IF	Citations
37	Promoting Transparency in Pharmaceutical Industryâ€“Sponsored Research. American Journal of Public Health, 2012, 102, 72-80.	1.5	65
38	Long-Term Risk for Device-Related Complications and Reoperations After Implantable Cardioverter-Defibrillator Implantation. Annals of Internal Medicine, 2016, 165, 20.	2.0	64
39	A Historic Moment for Open Science: The Yale University Open Data Access Project and Medtronic. Annals of Internal Medicine, 2013, 158, 910.	2.0	59
40	Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017. JAMA Network Open, 2020, 3, e203284.	2.8	58
41	Generic Atorvastatin and Health Care Costs. New England Journal of Medicine, 2012, 366, 201-204.	13.9	56
42	Place of Residence and Outcomes of Patients With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 749-756.	0.9	53
43	Development and Validation of an Algorithm to Identify Planned Readmissions From Claims Data. Journal of Hospital Medicine, 2015, 10, 670-677.	0.7	52
44	Aggregating multiple real-world data sources using a patient-centered health-data-sharing platform. Npj Digital Medicine, 2020, 3, 60.	5.7	51
45	Beyond insurance coverage: Usual source of care in the treatment of hypertension and hypercholesterolemia. Data from the 2003-2006 National Health and Nutrition Examination Survey. American Heart Journal, 2010, 160, 115-121.	1.2	48
46	Hospital Characteristics Associated With Risk-standardized Readmission Rates. Medical Care, 2017, 55, 528-534.	1.1	48
47	Overview and experience of the YODA Project with clinical trial data sharing after 5 years. Scientific Data, 2018, 5, 180268.	2.4	48
48	Regulatory Review of New Therapeutic Agents â€” FDA versus EMA, 2011â€“2015. New England Journal of Medicine, 2017, 376, 1386-1387.	13.9	47
49	Based On Key Measures, Care Quality For Medicare Enrollees At Safety-Net And Non-Safety-Net Hospitals Was Almost Equal. Health Affairs, 2012, 31, 1739-1748.	2.5	45
50	Sea Change in Open Science and Data Sharing. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 499-504.	0.9	43
51	Association of the FDA Amendment Act with trial registration, publication, and outcome reporting. Trials, 2017, 18, 333.	0.7	43
52	Association of Racial and Socioeconomic Disparities With Outcomes Among Patients Hospitalized With Acute Myocardial Infarction, Heart Failure, and Pneumonia. JAMA Network Open, 2018, 1, e182044.	2.8	42
53	Time for NIH to lead on data sharing. Science, 2020, 367, 1308-1309.	6.0	42
54	The relationship between systolic blood pressure on admission and mortality in older patients with heart failure. European Journal of Heart Failure, 2010, 12, 148-155.	2.9	41

#	Article	IF	Citations
55	Association Between Insurance Status and Access to Hospital Care in Emergency Department Disposition. JAMA Internal Medicine, 2019, 179, 686.	2.6	41
56	A Model for Dissemination and Independent Analysis of Industry Data. JAMA - Journal of the American Medical Association, 2011, 306, 1593.	3.8	40
57	Patterns and predictors of off-label prescription of psychiatric drugs. PLoS ONE, 2018, 13, e0198363.	1.1	40
58	Hospital-Based, Acute Care Use Among Patients Within 30 Days of Discharge After Coronary Artery Bypass Surgery. Annals of Thoracic Surgery, 2013, 96, 96-104.	0.7	37
59	US drug marketing: how does promotion correspond with health value?. BMJ: British Medical Journal, 2017, 357, j1855.	2.4	36
60	Assessment of Preprint Policies of Top-Ranked Clinical Journals. JAMA Network Open, 2020, 3, e2011127.	2.8	36
61	Certificate of Need Regulation and Cardiac Catheterization Appropriateness After Acute Myocardial Infarction. Circulation, 2007, 115, 1012-1019.	1.6	31
62	Poorly Cited Articles in Peer-Reviewed Cardiovascular Journals from 1997 to 2007. Circulation, 2015, 131, 1755-1762.	1.6	30
63	Regional Density of Cardiologists and Rates of Mortality for Acute Myocardial Infarction and Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 352-359.	0.9	29
64	Comparative Effectiveness of Generic Atorvastatin and Lipitor ^{Â®} in Patients Hospitalized with an Acute Coronary Syndrome. Journal of the American Heart Association, 2016, 5, e003350.	1.6	29
65	Financial Stress and Outcomes after Acute Myocardial Infarction. PLoS ONE, 2012, 7, e47420.	1.1	28
66	Characterisation of trials where marketing purposes have been influential in study design: a descriptive study. Trials, 2016, 17, 31.	0.7	28
67	Variation in the Diagnosis of Aspiration Pneumonia and Association with Hospital Pneumonia Outcomes. Annals of the American Thoracic Society, 2018, 15, 562-569.	1.5	27
68	Generic Drugs in the United States: Policies to Address Pricing and Competition. Clinical Pharmacology and Therapeutics, 2019, 105, 329-337.	2.3	27
69	Hospital variation in risk-standardized hospital admission rates from US EDs among adults. American Journal of Emergency Medicine, 2014, 32, 837-843.	0.7	25
70	Predictors of clinical trial data sharing: exploratory analysis of a cross-sectional survey. Trials, 2014, 15, 384.	0.7	24
71	Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study. Trials, 2018, 19, 581.	0.7	24
72	Noninferiority Designed Cardiovascular Trials in Highest-Impact Journals. Circulation, 2019, 140, 379-389.	1.6	24

#	Article	IF	Citations
73	Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2305-2314.	1.8	24
74	Cardiac Certificate of Need regulations and the availability and use of revascularization services. American Heart Journal, 2007, 154, 767-775.	1.2	23
75	Age of Data at the Time of Publication of Contemporary Clinical Trials. JAMA Network Open, 2018, 1, e181065.	2.8	23
76	Modernizing the FDAâ€™s 510(k) Pathway. New England Journal of Medicine, 2019, 381, 1891-1893.	13.9	23
77	Decision-making and cancer screening: A qualitative study of older adults with multiple chronic conditions. Journal of Geriatric Oncology, 2015, 6, 93-100.	0.5	22
78	Clinical research data sharing: what an open science world means for researchers involved in evidence synthesis. Systematic Reviews, 2016, 5, 159.	2.5	22
79	Emergency Department Volume and Outcomes for Patients After Chest Pain Assessment. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004683.	0.9	22
80	Leveraging Open Science to Accelerate Research. New England Journal of Medicine, 2021, 384, e61.	13.9	22
81	Coronary Artery Bypass Graft. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 214-221.	0.9	21
82	New and incremental FDA black box warnings from 2008 to 2015. Expert Opinion on Drug Safety, 2018, 17, 117-123.	1.0	21
83	When Choosing Statin Therapy. JAMA Internal Medicine, 2013, 173, 229.	2.6	20
84	Trends in Use of Ezetimibe After the ENHANCE Trial, 2007 Through 2010. JAMA Internal Medicine, 2014, 174, 1486.	2.6	20
85	Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines. Journal of General Internal Medicine, 2018, 33, 651-658.	1.3	20
86	Early experience with the FDAâ€™s Breakthrough Devices program. Nature Biotechnology, 2020, 38, 933-938.	9.4	20
87	Fulfilling the Promise of Unique Device Identifiers. Annals of Internal Medicine, 2018, 169, 183.	2.0	18
88	Consistency of trial reporting between ClinicalTrials.gov and corresponding publications: one decade after FDAAA. Trials, 2020, 21, 675.	0.7	18
89	Characteristics of available studies and dissemination of research using major clinical data sharing platforms. Clinical Trials, 2021, 18, 657-666.	0.7	18
90	Correlation of Inpatient and Outpatient Measures of Stroke Care Quality Within Veterans Health Administration Hospitals. Stroke, 2011, 42, 2269-2275.	1.0	17

#	Article	IF	Citations
91	Transfer Rates From Nonprocedure Hospitals After Initial Admission and Outcomes Among Elderly Patients With Acute Myocardial Infarction. JAMA Internal Medicine, 2014, 174, 213.	2.6	17
92	Association Between Food and Drug Administration Advisory Committee Recommendations and Agency Actions, 2008â€“2015. Milbank Quarterly, 2019, 97, 796-819.	2.1	17
93	Impact of the ENHANCE Trial on the use of ezetimibe in the United States and Canada. American Heart Journal, 2014, 167, 683-689.	1.2	16
94	Usual Source of Care and Outcomes Following Acute Myocardial Infarction. Journal of General Internal Medicine, 2014, 29, 862-869.	1.3	16
95	Use of Administrative Claims Models to Assess 30-Day Mortality Among Veterans Health Administration Hospitals. Medical Care, 2010, 48, 652-658.	1.1	15
96	Efficacy And Safety Concerns Are Important Reasons Why The FDA Requires Multiple Reviews Before Approval Of New Drugs. Health Affairs, 2015, 34, 681-688.	2.5	15
97	Risk-standardized Acute Admission Rates Among Patients With Diabetes and Heart Failure as a Measure of Quality of Accountable Care Organizations. Medical Care, 2016, 54, 528-537.	1.1	15
98	Availability of Clinical Trial Data From Industryâ€Sponsored Cardiovascular Trials. Journal of the American Heart Association, 2016, 5, e003307.	1.6	15
99	Determinants of Cardiac Catheterization Use in Older Medicare Patients With Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2010, 3, 54-62.	0.9	14
100	Data Desert for Inferior Vena Caval Filters. JAMA Cardiology, 2017, 2, 3.	3.0	14
101	A Nationwide Assessment of the Association of Smoking Bans and Cigarette Taxes With Hospitalizations for Acute Myocardial Infarction, Heart Failure, and Pneumonia. Medical Care Research and Review, 2017, 74, 687-704.	1.0	14
102	Defining Multiple Chronic Conditions for Quality Measurement. Medical Care, 2018, 56, 193-201.	1.1	14
103	State-Sponsored Public Reporting Of Hospital Quality: Results Are Hard To Find And Lack Uniformity. Health Affairs, 2010, 29, 2317-2322.	2.5	13
104	State Medicaid Programs Did Not Make Use Of Prior Authorization To Promote Safer Prescribing After Rosiglitazone Warning. Health Affairs, 2012, 31, 188-198.	2.5	13
105	US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009â€“2018. Clinical Trials, 2021, 18, 488-499.	0.7	13
106	Descriptions and Interpretations of the ACCORD-Lipid Trial in the News and Biomedical Literature. JAMA Internal Medicine, 2014, 174, 1176.	2.6	12
107	Early Experiences With Journal Data Sharing Policies: A Survey of Published Clinical Trial Investigators. Annals of Internal Medicine, 2018, 169, 586.	2.0	12
108	Data Sharing and Cardiology. Journal of the American College of Cardiology, 2017, 70, 3018-3025.	1.2	11

#	Article	IF	Citations
109	Characterizing the US FDA's approach to promoting transformative innovation. Nature Reviews Drug Discovery, 2015, 14, 740-741.	21.5	10
110	Regulatory Review of New Therapeutic Agents. New England Journal of Medicine, 2017, 376, 2598-2598.	13.9	10
111	Attribution of Adverse Events Following Coronary Stent Placement Identified Using Administrative Claims Data. Journal of the American Heart Association, 2020, 9, e013606.	1.6	10
112	Association of Inferior Vena Cava Filter Use With Mortality Rates in Older Adults With Acute Pulmonary Embolism. JAMA Internal Medicine, 2019, 179, 263.	2.6	9
113	Medicareâ€™s New Device-Coverage Pathway â€" Breakthrough or Breakdown?. New England Journal of Medicine, 2021, 384, e43.	13.9	9
114	A multicenter evaluation of computable phenotyping approaches for SARS-CoV-2 infection and COVID-19 hospitalizations. Npj Digital Medicine, 2022, 5, 27.	5.7	9
115	Do Imaging Studies Performed in Physician Offices Increase Downstream Utilization?. JACC: Cardiovascular Imaging, 2011, 4, 630-637.	2.3	8
116	Impact of Drug Policy on Regional Trends in Ezetimibe Use. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 589-596.	0.9	8
117	Merits of Data Sharing. Journal of the American College of Cardiology, 2017, 70, 1825-1827.	1.2	8
118	National Quality Assessment Evaluating Spironolactone Use During Hospitalization for Acute Myocardial Infarction (AMI) in China: China Patientâ€centered Evaluation Assessment of Cardiac Events (PEACE)â€Retrospective AMI Study, 2001, 2006, and 2011. Journal of the American Heart Association, 2015, 4, e001718.	1.6	7
119	Direct-to-consumer personal genomic tests need better regulation. Nature Medicine, 2021, 27, 940-943.	15.2	7
120	Updated Estimates of Pharmaceutical Company Payments to Physicians in Vermont. JAMA - Journal of the American Medical Association, 2008, 300, 1998.	3.8	6
121	Direct-to-Consumer Television Advertising: Time to Turn Off the Tube?. Journal of General Internal Medicine, 2013, 28, 862-864.	1.3	5
122	Physician clinical management strategies and reasoning: a cross-sectional survey using clinical vignettes of eight common medical admissions. BMC Health Services Research, 2014, 14, 176.	0.9	5
123	Medicare Formulary Coverage of Brand-Name Drugs and Therapeutically Interchangeable Generics. Journal of General Internal Medicine, 2020, 35, 1928-1930.	1.3	5
124	Payments for Acute Myocardial Infarction Episodes-of-Care Initiated at Hospitals With and Without Interventional Capabilities. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 882-888.	0.9	4
125	Quality of Care in the United States Territories, 1999â€"2012. Medical Care, 2017, 55, 886-892.	1.1	4
126	Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies. Journal of General Internal Medicine, 2019, 34, 2319-2321.	1.3	4

#	Article	IF	Citations
127	Digital medicine systems: an evergreening strategy or an advance in medication management?. BMJ Evidence-Based Medicine, 2019, 24, 203-204.	1.7	4
128	Confidentiality Orders and Public Interest in Drug and Medical Device Litigation. JAMA Internal Medicine, 2020, 180, 292.	2.6	4
129	Registration, publication, and outcome reporting among pivotal clinical trials that supported FDA approval of high-risk cardiovascular devices before and after FDAAA. Trials, 2021, 22, 817.	0.7	4
130	Accurate estimation of cardiovascular risk in a non-diabetic adult: detecting and correcting the error in the reported Framingham Risk Score for the Systolic Blood Pressure Intervention Trial population. BMJ Open, 2018, 8, e021685.	0.8	3
131	On Ghosts and Other Unwelcome Guests. Journal of General Internal Medicine, 2015, 30, 1389-1391.	1.3	2
132	Having Their Cake and Eating It Too: Physician Skepticism of the Open Payments Program. American Journal of Bioethics, 2017, 17, 19-22.	0.5	2
133	The Impact of Off-Patent Drug Acquisitions on Prices. Journal of General Internal Medicine, 2018, 33, 1007-1009.	1.3	2
134	Recent trends in use of inferior vena caval filters in US older adults with acute pulmonary embolism. Thrombosis Research, 2020, 186, 78-79.	0.8	2
135	Commentary on Bertagnolli et al.: Leveraging electronic health record data for clinical trialsâ€”a brave new world. Clinical Trials, 2020, 17, 243-246.	0.7	2
136	Demographic Characteristics of Participants in Trials Essential to US Food and Drug Administration Vaccine Approvals, 2010â€“2020. Journal of General Internal Medicine, 2022, 37, 700-702.	1.3	2
137	Cardiovascular outcomes and rates of fractures and falls among patients with brand-name versus generic L-thyroxine use. Endocrine, 2021, 74, 592-602.	1.1	2
138	Clinical studies sponsored by digital health companies participating in the FDAâ€™s Precertification Pilot Program: A cross-sectional analysis. Clinical Trials, 2022, 19, 119-122.	0.7	2
139	Incremental Revisions across the Life Span of Ophthalmic Devices after Initial Food and Drug Administration Premarket Approval, 1979â€“2015. Ophthalmology, 2017, 124, 1237-1246.	2.5	2
140	Rates of, and factors associated with, switching among generic levothyroxine preparations in commercially insured American adults. Endocrine, 2022, 76, 349-358.	1.1	2
141	Medical Device User Fee Reauthorization â€” Back to Basics or Looking Ahead?. New England Journal of Medicine, 2022, 387, 196-199.	13.9	2
142	Moving Forward From rhBMP-2. Spine, 2014, 39, 531-532.	1.0	1
143	Commentary: Diagnostic devices in clinical trials have high stakes for patient care. BMJ, The, 2016, 354, i5197.	3.0	1
144	Quantifying the utilization of medical devices necessary to detect postmarket safety differences: A case study of implantable cardioverter defibrillators. Pharmacoepidemiology and Drug Safety, 2018, 27, 848-856.	0.9	1

#	Article	IF	Citations
145	Systematic overview of Freedom of Information Act requests to the Department of Health and Human Services from 2008 to 2017. Research Integrity and Peer Review, 2019, 4, 26.	2.2	1
146	Impact of left ventricular assist devices and heart transplants on acute myocardial infarction and heart failure mortality and readmission measures. PLoS ONE, 2020, 15, e0230734.	1.1	1
147	Drug labeling changes and pediatric hematology/oncology prescribing: Measuring the impact of U.S. legislation. Clinical Trials, 2021, 18, 174077452110306.	0.7	1
148	Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publicationsâ€“4. Mayo Clinic Proceedings, 2010, 85, 199-200.	1.4	0
149	Submissions from the SPRINT Data Analysis Challenge on clinical risk prediction: a cross-sectional evaluation. BMJ Open, 2019, 9, e025936.	0.8	0
150	Non-inferiority trials using a surrogate marker as the primary endpoint: An increasing phenotype in cardiovascular trials. Clinical Trials, 2020, 17, 723-728.	0.7	0
151	Physician Network Connections Associated With Faster De-Adoption of Dronedarone for Permanent Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e008040.	0.9	0
152	Public Misinformation and Science Communication in Times of Public Health Crises. Clinical Chemistry, 0, , .	1.5	0